Twist Bioscience CEO Robert Chess sold $181,696 worth of stock Via Investing.com

Robert Chess, director of Twist Bioscience Corp (NASDAQ:), a biotechnology company with a market capitalization of $2.82 billion, recently sold shares of the company’s stock, according to a report by control. To follow InvestingPro data, TWST has shown strong momentum with a 30.67% year-to-date gain, although the stock remains flat. On December 5, Chess sold a total of 3,504 shares, generating approximately $181,696. Shares were traded at a price ranging from $51.7025 to $52.4511 per share. This process was carried out under a previously established business plan.

In addition to the sale, Chess exercised options, acquiring 3,504 shares at a price of $8.82 each, which is $30,905. Pursuant to these transactions, Chess owns 21,641 shares directly and another 42,528 indirectly through the Chess 1997 Trust.

In other recent news, Twist Bioscience has been active in the financial arena. The company’s 2024 fiscal year ended with a 27% increase in Q4 revenue to $84.7 million and annual revenue growth of 28%, reaching $330 million. The company also exceeded its overall guidance for the quarter, reaching 45.1%, and saw a year-over-year improvement of 42.6%.

Analysts from Baird, TD Cowen, and Scotiabank (TSX 🙂 all shared their positive feelings about Twist Bioscience. Baird maintained an Outperform rating and increased the price target to $48. Scotiabank raised its price target for the company to $54, maintaining a Sector Outperform rating. TD Cowen affirmed a Buy rating on Twist Bioscience, highlighting the company’s firm financial guidance for fiscal year 2025.

Twist Bioscience’s preliminary guidance for FY25 expects revenue growth between 17% to 20% year-on-year, largely driven by Next (LON:) Branches of Next Generation Sequencing (NGS) and Synthetic Biology (SynBio). The company is also expected to improve its adjusted EBITDA by around 30 billion for the year. These recent developments indicate a promising future for Twist Bioscience.

This article was created with the support of AI and reviewed by the editor. For more details, see our T&C.